B7-1 AND 4-1BB LIGAND EXPRESSION ON A MYELOMA CELL LINE MAKES IT POSSIBLE TO EXPAND AUTOLOGOUS TUMOR-SPECIFIC CYTOTOXIC T CELLS IN VITRO
B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.
Zhao-Yang Lu, Maud Condomines, Karin Tarte and B7-2 which activate the CD28 T cell activation molecule [1, 2] . Engagement of TCR by peptide-MHC complexes without costimulatory molecules results in profoundly anergic T cells which are unable to respond to further activation [3, 4] . B7/CD28 T cell activation is downregulated by CTLA-4 [2, 5] . CTLA-4 is another B7 ligand that is expressed later by T cells which results in T cell inactivation following activation by B7 molecules. The family of B7-like costimulatory molecules is rapidly expanding as demonstrated by the recent discoveries of B7h/B7RP-1, B7-H1/PDL-1, and B7-DC/PDL-2, which bind ICOS T cell activating molecule and PD1 inhibitory molecule, respectively, and B7H3, which binds an unknown activating receptor [6] . Another class of costimulatory molecules belongs to the TNF/TNF receptor family. OX-40 ligand triggers OX-40 + T cells and results in long-term expansion of CD4 + T cells [7] . LIGHT can stimulate the receptor HVEM present on CD4 + and CD8 + T cells. The 4-1BB ligand (4-1BBL) binds to 4-1BB present on activated T cells and induces NF-KB, c-jun, and P38 signaling pathways which sustain B-7/CD28-mediated activation [8] . 4-1BBL prevents activation-induced apoptosis of CD8 + T cells, increases T cell effector function, and enhances clonal proliferation and survival of CD8 + cytotoxic T cells [9, 10] . 4-1BBL is expressed on dendritic cells, monocytes, and other myeloid cells.
B7-1 AND 4-1BB LIGAND EXPRESSION ON A MYELOMA CELL LINE MAKES IT POSSIBLE TO EXPAND AUTOLOGOUS TUMOR-SPECIFIC CYTOTOXIC T CELLS IN VITRO
The 4-1BB molecule is expressed by activated CD4  + and CD8  + T cells but also by NK   cells, NK-T cells, and CD4   +   CD25 + regulatory T cells [8] .
Tumor cells are generally poor APC due to a defect in costimulatory molecules and/or peptide presentation through MHC molecules [11, 12] . 4-1BBL improves the efficacy of antigen presentation in various tumor models [13] . In particular, administration of an agonist anti-4-1BB monoclonal antibody induced a strong anti-tumor immunity in mice [14, 15] .
Multiple myeloma (MM) is a B cell neoplasia affecting the late stage of B cell differentiation. Although high-dose chemotherapy and autologous stem cell transplantation have improved the rate of complete remission, some multiple myeloma cells (MMC) escape treatment and all MM patients relapse [16] . The development of immunotherapy designed to enhance cytotoxic T lymphocyte (CTL) eradication or control of residual tumor cells may be one hopeful approach to improve MM treatment. However, MMC are poor APC. They express CD40 molecules that are nonfunctional in terms of B7 induction after triggering with CD40 ligand [17] . Interestingly, transduction of MMC with B7-1 retrovirus can confer them immunogenicity [17] . However, no long-term expansion of anti-tumor CTL could be obtained. Here, we demonstrate that transduction of B7-1 and 4-1BBL in human myeloma cell lines (HMCLs) made it possible to stimulate long-term anti-myeloma CTL.
Patients, Materials and Methods

Patient and healthy donor samples
Seven newly-diagnosed patients with MM (median age: 64.5 years) were included in this study. There were 3 IgG, 2 IgG, 1 IgA and 1 Bence-Jones MM. Bone-marrow aspirates were collected for the determination of plasma cell labeling index (PCLI), a marker of disease activity, and excess cells were used for this study after written informed consent. Bone marrow mononuclear cells (BMMC) were isolated by Ficoll-Hypaque centrifugation (Biowhittaker, Walkersville, MD, USA). HMCLs have been obtained by growing MMC from patients with extramedullary proliferation with IL-6 and GM-CSF, as
reported [18] . For 3 HMCLs (XG-5, XG-13, and XG-19), the autologous and nonmalignant B-lymphoblastoid cell line (EBV-5, EBV-13 and EBV-19) were established by in vitro EBV infection of peripheral blood B cells, as described [19] . Peripheral blood T cells from the patient from whom XG-19 was derived were also collected and frozen. Peripheral blood from 5 healthy donors was obtained after informed consent.
Antibodies and cytokines
Monoclonal antibodies (mAbs) conjugated to FITC or phycoerythrin (PE) were used for staining of cells and phenotypic analyses. Anti-4-1BB (PE); anti-4-1BBL (PE); anti-CD27 
Generation of dendritic cells
Immature dendritic cells (DC) were generated from leukapheresis products of MM patients, as previously described [21] . B7-1/4-1BBL XG) were subsequently maintained with 600 g/ml of G418.
Mixed lymphocyte reaction (MLR)
To evaluate HMCL-induced T cell proliferation, allogeneic and autologous MLR were 
Generation of autologous anti-tumor T cells
From one patient with plasma cell leukemia, peripheral blood mononuclear cells 
T cell cloning
The responder T cells were seeded at different cell concentrations ( weeks. The T cell clones, taken 2 weeks after the last stimulation, were used in cytotoxicity and Elispot assays.
T cell repertoire study
T cell clone total RNA was prepared by a modification of the Chomczyski and Sacchi method [22] with the Trizol reagent (GIBCO-BRL). RT-PCR were performed with 24 different TCRBV subfamily-specific primers and one C consensus primer, followed by a runoff reaction with a fluorescent C primer, as described [23] .
IFN- Elispot assay
IFN- production by activated T cells was evaluated using an IFN- Elispot kit (Diaclone, Besançon, France) according to the manufacturer's instructions. Briefly, 96-well multiscreen plates were coated overnight with 100 l/well of 10 g/ml primary anti-IFN- mAb in PBS, then washed three times with PBS containing 0.25% Tween20 (Sigma) and blocked with PBS containing 5% FCS for 2 h at 37°C. 
Results
Myeloma cells do not express 4-1BBL and 4-1BB molecules
We first looked for MMC expression of the 4-1BBL costimulatory molecule. As shown in but did express CD28, a T cell activation molecule, in agreement with our previous report [24] . We confirmed that these HMCLs fail to express B7-1 and express a low density of B7-2. Most of the cell lines expressed CD70/CD27L but not the CD27 T and B cell activation molecule. In addition, these cell lines failed to express HLA class II but expressed HLA class I molecules and adhesion molecules (CD54, CD58) known to be important in T cell/APC interaction ( [17] and unpublished results). We also investigated the 4-1BBL expression on purified MMC from 7 newly diagnosed patients. Results are shown in Table 2 . Patients' MMC did not express 4-1BBL or B7-1. They expressed a low density of B7-2. Contrary to HMCLs, primary MMC did not express CD70 but did express CD27.
Stimulation of myeloma CD40, with or without IL-2 and IL-12 did not induce B7-1 and 4-1BBL on myeloma cells
MMC expressed CD40 molecules (Table 1 and 2) but a coactivation with a CD40L transfectant in the presence of IL-2 or IL-2 and IL-12 did not induce B7-1 (Table 3) , contrary to a previous report [25] . In fact, in this report, the induction of B7-1 in MMC after CD40L and IL-2 stimulation was found in only one out of 5 samples and at a marginal level. As a control, CD40L transfectant can upregulate B7-1 and B7-2 on human dendritic cells in 3 separate experiments ( Table 3 ). The CD40L transfectant did not induce 4-1BBL on HMCLs. This CD40L transfectant did not also induce 4-1BBL expression on human dendritic cells. Such a 4-1BBL upregulation was previously shown for murine dendritic cells [26] but we could not confirm these data.
Obtaining HMCLs that expressed B7-1 and/or 4-1BBL by retroviral gene transfer
As indicated in Fig. 1 , HMCLs expressing a large density of B7-1, 4-1BBL, or B7-1 and 4-1BBL were obtained after retroviral transduction, G418 selection, and cell sorting.
Induction of B7-1 and/or 4-1BBL did not affect the growth of myeloma cells that expressed CD28. It remained strictly dependent on the addition of exogenous IL-6 despite a continuous triggering of CD28 in B7-1 transfectants (results not shown). This is in agreement with the reported lack of growth stimulating activity of CD28 triggering in MMC [24] . In addition, the expression of 13 main immune molecules was unaffected by 4-1BBL or B7-1 transduction (Fig. 2) . In particular, no change in the density of HLA class I, CD54, or CD58 were found. We observed a decrease in CD28 density in B7-1 transfectant probably due to a masking or downregulation of CD28 epitope.
4-1BBL and/or B7-1 HMCLs strongly stimulate allogeneic T cells
The 3 
Anti-myeloma T cell clones
One of the three T cell lines was cloned in limiting dilution using B7- Fig. 6a . However, no blockage of the cytotoxicity activity was observed adding an anti-MHC class I mAb. This could be explained by a high affinity of the TCR for peptide-MHC class I complex. The second group of 10 clones, called "pan myeloma", also killed other HMCLs and the cytotoxic profile of one of these clones (II-1B/A-10) is shown in Fig. 6b. This clone displayed only a single peak using PCR amplification of TCRBV transcript size pattern (data not shown). Clone II-1B/A-10 killed XG-19, XG-4, XG-7, XG-5, XG-13, L363, and the patient's primary MMC from whom the XG-19 HMCL was obtained (Fig. 6b) . Table 4 . No common HLA class I allele could be found among the 4 strongly killed HMCLs (XG-4, XG-5, XG-7 and XG-13). However, a same MHC class I epitope can be efficiently presented by different MHC class I alleles [27, 28] . Another explanation is that this 4h-killing is not triggered by TCR recognition of MHC/peptide complexes but induced by other MHC independent mechanisms as NKG2D/MICA-B, in agreement with a lack of blockage of the cytotoxic activity by an anti-MHC class I mAb. However, using gene expression profiling, no differences in the expression of MICA or MICB were found between the 4 highly killed HMCLs and the other poorly killed HMCLs (data not shown).
In addition, these T cell clones produced IFN- in response to stimulation by the parental XG-19, unlike EBV-19 cell line, that was blocked by an anti-MHC class I mAb (Fig.7) . T cell responses, as demonstrated for anti-viral cytotoxic T cells [37] . A putative protocol to obtain anti-myeloma cell T lymphocytes would be to perform one or two stimulations by the B7-1/4-1BBL-transduced MMC followed by stimulations with MMC transduced with 4-1BBL only in order to avoid a negative signal mediated by B7-1/CTLA-4 engagement.
Discussion
Conversely, using myeloma cells as APC, expanded T cells will not contain CD4 + T cells.
This may result in a lack of help and in an eventually weak immune reaction, once T cells are infused [38] . to tumor antigen, and that effector cells generated through 4-1BB and CD28 costimulation mediated potent in vivo tumor regression in mice [44] . However, 4-1BB ligation may have a dual role since administration of anti-4-1BB mAbs in mice has been shown to abrogate T cell dependent humoral immunity [45] or to generate CD8 + T cells with potent suppressive function [46] . Finally, using several partially HLA-matched HMCLs transduced with costimulatory molecules as a whole tumor vaccine could be envisaged in MM vaccination strategies.
In summary, our results showed that a T cell repertoire recognizing tumor antigens persisted in the peripheral blood of patients with multiple myeloma even at the terminal stage, and that this T cell repertoire could be activated and amplified by autologous tumor cells transduced with the costimulatory molecules B7-1 and 4-1BBL. Cells were harvested during the exponential growth phase and were stained with the indicated PE-conjugated mAb or PE-conjugated control mAb and the fluorescence analyzed with a FACSscan device. In brackets are the mean fluorescence intensities obtained with the mAb for an intensity set between 4-6 with a control mAb. Patients' myeloma cells were purified and stained with the indicated PE-conjugated mAb or PE-conjugated control mAb. The fluorescence was analyzed with a FACSscan device.
Data are the percentages of labeled cells. with 5% human AB serum. IL-2 (10 U/ml) was added after three days and then twice a week.
Results are the T cell number in culture wells of one experiment representative of 3. Cell-mediated toxicity was determined after a 4 hour stimulation using a standard The IFNElispot assay was performed with the clone whose cytotoxic profile is shown in Fig.6A . 
